30 Oct 2015 16:20
Amphion Innovations plc
("Amphion" or "the Company")
The following amendment has been made to the 'Death of a Director' announcement released on 30 October 2015 at 3.50pm under RNS No 0917E
The release date of the announcement is 30 October 2015. The previous announcement incorrectly listed it as 30 September 2015.
All other details remain unchanged.
The full amended text is shown below.
Death of a Director
London and New York, 30 October 2015 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, sadly announces that R. James Macaleer, the Company's Chairman, passed away on Thursday 29 October 2015.
Richard Morgan, CEO of Amphion, said, "It is with a heavy heart that we announce the passing of our Chairman, Jim Macaleer. Jim was a long-time friend and steadfast supporter of Amphion and he will be sorely missed. The Company is grateful to have the full support of his family going forward."
The Company will update the market in due course on changes to the board.
For further information please contact:
Amphion InnovationsCharlie Morgan+1 212 210 6224Yellow Jersey PR
Charles Goodwin / Dominic Barretto+44 (0)7747 788 221Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Duncan Monteith (Corporate Finance)Charlie Leigh-Pemberton (Corporate Broking)+44 (0)20 7886 2500
Northland Capital Partners Limited (Joint Corporate Broker) Patrick Claridge / David Hignell (Corporate Finance)John Howes / Mark Treharne (Corporate Broking)+44 (0)20 7382 1100
Plumtree Capital Limited (Financial Adviser)Stephen Austin+44 (0)20 7183 2493+646 568 7502
About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.
We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.
On the web: www.amphionplc.com